| Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma |
|
JiHyun Song, HeeKyung Kim, SukPyo Shin, InJai Kim, Doyeun Oh, SoYoung Chong |
|
Division of Hematology-Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea |
| 다발골수종 환자에서 보르테조밉(bortezomib) 투여 후 발생한 심부전 1예 |
|
송지현, 김희경, 신석표, 김인재, 오도연, 정소영 |
|
차의과학대학교 분당차병원 혈액종양내과 |
Correspondence:
SoYoung Chong, Tel: +82-31-780-5284, Fax: +82-31-780-5221, Email: sychong@cha.ac.kr
|
|
Received: 7 May 2014 • Revised: 7 July 2014 • Accepted: 28 July 2014 |
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
Bortezomib (Velcade®) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that the accumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomib treatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient with multiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routine cardiac monitoring. |
| Key Words:
Bortezomib; Heart failure; Multiple myeloma |
| 주제어:
보르테조밉; 심부전; 다발골수종 |
|
PDF Links
Full text via DOI
Download Citation
